Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RiFL: Rifaximin in Fatty Liver Disease. Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)?

NCT01355575 is registered in ClinicalTrials.gov with Imperial College London as lead sponsor.

NCT NCT01355575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01355575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RiFL: Rifaximin in Fatty Liver Disease. Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)?
Lead sponsor
Imperial College London
Phase
Phase 4
Overall status
Terminated
Start date
May 31, 2011
Completion date
September 30, 2012
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nafld, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis